Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interim analysis: Open-label extension study of leniolisib for patients with APDS.

The Journal of allergy and clinical immunology - 1 Jan 2024

Rao V Koneti, Kulm Elaine, Šedivá Anna, Plebani Alessandro, Schuetz Catharina, Shcherbina Anna, Dalm Virgil A, Trizzino Antonino, Zharankova Yulia, Webster Sharon, Orpia Alanvin, Körholz Julia, Lougaris Vassilios, Rodina Yulia, Radford Kath, Bradt Jason, Relan Anurag, Holland Steven M, Lenardo Michael J, Uzel Gulbu

Abstract excerpt

BACKGROUND: Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS; or p110δ-activating mutations causing senescent T cells, lymphadenopathy, and immunodeficiency) is an inborn error of immunity caused by PI3Kδ hyperactivity. Resultant immune deficiency and dysregulation lead to recurrent sinopulmonary infections, herpes viremia, autoimmunity, and lymphoproliferation. OBJECTIVE: Leniolisib, a selective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunologic Deficiency Syndromes

Share to Mutation

Share to Phosphatidylinositol 3-Kinases

Share to Quality of Life

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 37797893
DOI: 10.1016/j.jaci.2023.09.032
PMCID: PMC10841669

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interim analysis: Open-label extension study of leniolisib for patients with APDS.PMID 37797893Read ↗

Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.Semantic proximity Read ↗

Comparative efficacy of leniolisib (CDZ173) versus standard of care on rates of respiratory tract infection and serum immunoglobulin M (IgM) levels among individuals with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): an externally controlled studySemantic proximity Read ↗

A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): Adolescent and adult subgroup analysisSemantic proximity Read ↗

Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies.Semantic proximity Read ↗

Expert insights on Hodgkin's lymphoma development in an activated PI3K delta syndrome patient undergoing leniolisib treatment.Semantic proximity Read ↗

Activated phosphoinositide 3‐kinase delta syndrome: Pathogenesis, clinical manifestations, and treatmentSemantic proximity Read ↗

Report of the Italian Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome in the Target Therapy Era.Semantic proximity Read ↗

An updated review on activated PI3 kinase delta syndrome (APDS)Semantic proximity Read ↗

Infections in activated PI3K delta syndrome (APDS).Semantic proximity Read ↗

Systematic review of mortality and survival rates for APDS.Semantic proximity Read ↗

Real-world evidence of mortality and survival rates in 256 individuals with APDSSemantic proximity Read ↗

The Treatment of Activated PI3Kδ SyndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.